Barbara Oil Co. Acquires New Shares in Axon Enterprise, Inc $AXON

Barbara Oil Co. bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,695 shares of the biotechnology company’s stock, valued at approximately $963,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after purchasing an additional 53,060 shares during the period. Geode Capital Management LLC raised its holdings in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after buying an additional 35,544 shares during the period. Baillie Gifford & Co. lifted its position in Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the last quarter. Sands Capital Management LLC lifted its position in Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after buying an additional 167,095 shares during the last quarter. Finally, Edgewood Management LLC purchased a new position in Axon Enterprise during the fourth quarter worth about $846,516,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 1.8%

Shares of AXON opened at $435.39 on Wednesday. The stock has a market capitalization of $35.09 billion, a PE ratio of 174.86, a P/E/G ratio of 8.06 and a beta of 1.45. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The company’s 50-day simple moving average is $411.40 and its 200-day simple moving average is $487.65.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. During the same quarter in the previous year, the business posted $1.47 earnings per share. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. Analysts forecast that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Craig Hallum reiterated a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a research report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on shares of Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Morgan Stanley set a $600.00 target price on Axon Enterprise in a research report on Thursday, May 7th. Finally, Barclays decreased their price target on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the transaction, the president owned 169,125 shares in the company, valued at $82,609,106.25. The trade was a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CRO Cameron Brooks sold 1,242 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at $24,855,000. This represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 38,989 shares of company stock worth $19,090,083 over the last three months. 4.20% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.